Jianjia Robotics Secures Hundreds of Millions in Series C Funding and Files for IPO as a Leading Hard-Tissue Surgical Robotics Platform

Recently, Jianjia Robot, a platform enterprise specializing in hard-tissue surgical robots, completed a Series C financing round amounting to hundreds of millions of RMB. The round was led by LYFE Capital, with participation from SBCVC, while existing investors GL Ventures and Fosun Pharma continued to increase their stakes. The company has raised nearly RMB 400 million in financing over the past year. Haoyue Capital served as the exclusive financial advisor for this round. The funds will be used to advance clinical trials for its knee arthroplasty surgical robot, as well as for the research and development and clinical registration of new products, including other surgical robots.

Jianjia Robot, founded in 2018, has rapidly emerged as a leading domestic platform enterprise for hard-tissue surgical robots, leveraging its team’s extensive prior experience in the field of surgical robotics, outstanding integration of medical and engineering expertise, and strong execution capabilities. Currently, the company’s hip replacement surgical robot has completed clinical enrollment and follow-up. It is also the first “total hip replacement surgical robot” product in China to enter the National Medical Products Administration (NMPA) Special Review Procedure for Innovative Medical Devices, positioning it to potentially become the first domestically produced joint replacement surgical robot to receive approval. In addition, the company has multiple new products, including various surgical robots, in the research and development and testing submission stages.

Extensive clinical evidence demonstrates that robot-assisted minimally invasive joint replacement surgery significantly improves overall precision, reduces the incidence of postoperative dislocation and leg-length discrepancy, shortens patient recovery time, enhances patient satisfaction, and lowers potential additional medical costs. According to existing clinical data, Jianjia’s hip joint robotic system can control final surgical error within 1 mm and implantation angle deviation within 1°, substantially addressing longstanding clinical challenges associated with conventional hip arthroplasty, such as suboptimal manual operative precision, a steep learning curve, and chronic intraoperative radiation exposure for surgeons. Compared with currently available robotic systems in clinical practice, Jianjia’s product features significant optimizations in preoperative planning, registration, and calibration, offers additional support for femoral-side processing, and functions as an open platform compatible with prostheses from various manufacturers, thereby presenting clear competitive advantages.

Leveraging the team’s extensive expertise in the field of surgical robotics, the company has expanded its product pipeline to include knee replacement surgical robots and other robotic surgical systems. Notably, the knee robot is scheduled to commence formal clinical trials in the near future, thereby extending the company’s technological advantages from the hip joint domain to the knee.

For consecutively securing investments from renowned institutions,Dr. Xu Jing, Founder of Jianjia RobotIt was stated that the success of traditional joint replacement surgery heavily relies on the surgeon’s experience and skills. In the future, the application of robotic-assisted joint surgery will become the sole breakthrough for improving prosthetic implantation accuracy and facilitating the scale-up of joint replacement procedures. The company is honored to have partnered with renowned investment institutions including LYFE Capital, SBCVC, GL Ventures, Shanghai Fuxing Medicine Investment Co., Ltd., BV Baidu Venture Capital, Kefa Capital, and Puhua Capital across several financing rounds. Additionally, the company has established commercial collaborations with multiple leading domestic and international joint implant manufacturers to build an open-platform robotic system for joint surgery aimed at benefiting patients. The company will also fully accelerate the R&D and clinical registration of its existing products, fundamentally addressing current clinical pain points such as suboptimal outcomes in joint replacement surgeries and the steep learning curve for surgeons. With a focus on intelligence and precision therapy, the company aims to drive the development of orthopedic surgery in China.

Chen Gang, Partner at LYFE Capitalstated that Founder Dr. Xu and his team demonstrate strong industry foresight and execution capabilities. Over the past three years, they have keenly capitalized on the industry trend shifting from traditional joint replacement surgery toward digitalization and precision, successfully developing robotic systems for hip and knee surgeries. Furthermore, they have built a comprehensive ecosystem of precision surgical product lines around this platform. LYFE Capital remains bullish on the team’s R&D prowess and commercial execution capabilities, and will provide long-term support to help the company become an industry-leading platform enterprise in hard-tissue surgical robotics.

Jiang Min, Partner at SBCVCWe have stated that digital health and medical technology are our key strategic focus areas, and surgical robots represent a prime example of the convergence of these two fields. Surgical robots offer significant clinical advantages, including improved surgical precision, better complication control, reduced learning curves for surgeons, and shortened training cycles, making them a critical technology in the evolution of surgical practice. As a leading Chinese manufacturer of orthopedic joint surgical robots, Jianjia Robot has taken the lead in completing clinical trials for hip replacement surgery, which entails higher technical requirements, while also expanding indications for knee replacement procedures, thereby positioning itself at the forefront of the industry. Currently, there is a substantial gap in joint replacement penetration rates between China and the United States, indicating strong growth prospects for the domestic joint replacement market. We are confident that Jianjia Robot will help address the unmet clinical needs for joint replacements in China, serving the vast number of patients suffering from joint diseases, and we will continue to support Jianjia Robot’s international expansion efforts.

Yi Nuoqing, Co-Chief Investment Officer of Hillhouse Capital and Head of Biopharmaceuticals and Medical Devices at Hillhouse VenturesIt was stated that surgical robots, as representatives of digital and intelligent medical devices, have become a key area of increased R&D investment for major global medical device manufacturers in recent years. As one of the leading enterprises in China’s orthopedic surgical robot sector, Jianjia Robot demonstrates exceptional organizational efficiency and R&D capabilities. Its product portfolio has expanded from hip joint robots to knee joint robots, as well as multiple other hard-tissue surgical robots. GL Ventures remains bullish on Jianjia Robot and will support the company’s continuous growth by providing talent, resources, and technological expertise, aiming to help Jianjia become an innovative leader in the field of digital and intelligent medical devices.

Liu Yi, Vice President of Fosun Pharma and Chairman of the Medical Device DivisionIt was stated that the accelerating pace of population aging has led to a year-on-year increase in the demand for joint replacement surgeries. In recent years, the development goals for joint replacement surgery have been to improve surgical precision, shorten patient recovery time, and enable the procedure to be performed in more hospitals. Surgical robots provide an effective solution for enhancing the accuracy and consistency of joint replacement surgeries. As a start-up in the domestic orthopedic robotics sector, Jianjia Robot’s core R&D team features a background in “medical-engineering integration,” with members possessing extensive experience and resources in robot development. Despite being established only three years ago, the company’s first hip replacement surgical robot has successfully completed clinical enrollment and follow-up, marking its industrialization progress as industry-leading. Fosun Pharma’s wholly-owned subsidiary, China Medical Systems International (CMSI), has accumulated substantial experience and resources in the commercialization of various types of surgical robots. CMSI is now collaborating with Jianjia Robot on pre-market preparations and will spare no effort in supporting Jianjia Robot’s market promotion and global clinical resource alignment. We look forward to the early clinical application of Jianjia Robot’s technology, providing cost-effective, precise orthopedic surgical solutions for patients in China and around the world.

Yang Zhenjun, Partner at Haoyue CapitalIt was stated that Jianjia Robot, established just three years ago, has completed clinical follow-up for its first hip replacement surgical robot product and is poised to become the first domestically produced joint replacement surgical robot to receive approval. The company’s profound expertise in the field of surgical robotics, robust R&D capabilities integrating medical and engineering disciplines, and high execution efficiency are truly admirable. Haoyue Capital is honored to have served as the exclusive financial advisor to Jianjia Robot for three consecutive funding rounds. We remain bullish on the company’s platform expansion capabilities in the realm of hard-tissue surgical robotics and believe that once its surgical robot products are approved and launched, they will greatly benefit a wide range of patients.

LYFE Capital is a healthcare-focused investment fund established in 2015, dedicated to investing in healthcare companies with exceptional management teams and visionary goals in the Chinese and U.S. markets. Its investment portfolio spans innovative biopharmaceuticals, medical devices, and medical diagnostics. LYFE Capital works closely with its portfolio companies, providing not only financial support but also assistance in business development, identifying overseas partners, and actively supporting strategic and team enhancements to facilitate product approvals and market access. For LYFE Capital, portfolio companies are not merely investment projects but long-term partners.

SoftBank China Capital (SBCVC), established in 2000, is a venture capital and private equity fund management firm dedicated to investing in high-growth, high-tech enterprises across the Greater China region. It has successfully invested in a portfolio of outstanding companies, including Alibaba, Taobao, Focus Media, GDS Holdings, BGI Genomics, Dian Diagnostics, and Edan Instruments. Currently, SBCVC manages multiple USD and RMB funds, with investment sectors spanning information technology, healthcare, clean technology, and advanced manufacturing, covering investment stages from early-stage to growth-stage and late-stage. The SBCVC team boasts successful entrepreneurial backgrounds, extensive operational experience, and deep technical expertise, complemented by a strong track record in investment performance. The firm supports portfolio companies’ development through strategic planning, market expansion, resource integration, and talent acquisition.

GL Ventures, the venture capital arm of Hillhouse Capital, is a startup investment fund dedicated to early-stage innovative companies. Its focus areas include software and hard technology, biopharmaceuticals and medical devices, consumer internet and technology, and emerging consumer brands. Biopharmaceuticals and medical devices have long been core investment priorities for Hillhouse. Over the past decade, Hillhouse has invested in more than 200 outstanding enterprises in the biopharmaceutical, medical device, and healthcare services sectors. We aim to partner with companies as “friends of time,” jointly driving innovation and development in the broader health industry to benefit more patients.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock codes: 600196.SH, 02196.HK), founded in 1994, is a leading, innovation-driven international pharmaceutical and healthcare group in China. The Company has strategically positioned itself across the pharmaceutical and healthcare value chain, with directly operated businesses spanning pharmaceuticals, medical devices and diagnostics, and healthcare services, while also extending into pharmaceutical distribution through its equity stake in Sinopharm Group Co., Ltd. Looking ahead, Fosun Pharma will adhere to its “4IN” strategy—Innovation, Internationalization, Integration, and Intelligentization—and uphold its development model of “innovation-led transformation, integrated operations, and steady growth,” along with its commitment to sustainable development, striving to become a top-tier enterprise in mainstream global healthcare markets.

Haoyue Capital was established in January 2014, with a commitment to serving as a bridge connecting China’s healthcare industry with capital. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with extensive experience in China’s healthcare sector. By closely monitoring market dynamics and investment trends in healthcare over the long term, the firm releases weekly healthcare investment updates and thematic research reports, offering Haoyue’s perspectives on new policies and emerging frontiers.